Table 1. Baseline levels of soluble proteins and ratios of C1D28 to baseline levels during sunitinib treatment.
| Biomarker | All patients, median (range) | N | P-value | Carcinoid tumour, median (range) | N | pNET, median (range) | N | P-valuea |
|---|---|---|---|---|---|---|---|---|
| VEGF Baseline, pg ml−1 | 38.6 (8.2–408.5) | 101 | 30.1 (9.2–138.9) | 37 | 43.4 (8.2–408.5) | 64 | 0.069 | |
| VEGF C1D28:C1D1 | 3.4 | 100 | <0.0001 | 3.6 | 35 | 3.2 | 65 | 0.599 |
| sVEGFR-2 Baseline, pg ml−1 | 9120 (3251–15 689) | 104 | 8722 (3251–12 776) | 39 | 9562 (3894–15 689) | 65 | 0.041 | |
| sVEGFR-2 C1D28:C1D1 | 0.7 | 102 | <0.0001 | 0.8 | 37 | 0.6 | 65 | 0.105 |
| sVEGFR-3 Baseline, pg ml−1 | 100 850 (30 700–2 569 000) | 104 | 96 800 (43 500–2 569 000) | 39 | 100 800 (30 700–168 400) | 65 | 0.817 | |
| sVEGFR-3 C1D28:C1D1 | 0.6 | 98 | <0.0001 | 0.6 | 34 | 0.6 | 64 | 0.429 |
| IL-8 Baseline, pg ml−1 | 16.9 (3.3–763.1) | 104 | 15.0 (3.3–763.1) | 39 | 17.6 (6.1–130.3) | 65 | 0.302 | |
| IL-8 C1D28:C1D1 | 1.8 | 99 | 0.008 | 1.4 | 36 | 1.8 | 66 | 0.528 |
| SDF-1α Baseline, pg ml−1 | 583.4 (209.9–2218.8) | 28 | 414.8 (209.9–2218.8) | 14 | 1235.7 (285.7–2049.8) | 14 | 0.003 | |
| SDF-1α C1D28:C1D1 | 1.2 | 21 | 0.027 | 1.8 | 10 | 1.1 | 11 | 0.053 |
Abbreviations: C(N)D(N)=cycle number, day number; IL-8=interleukin 8; pNET=pancreatic neuroendocrine tumour; SDF-1α=stromal cell-derived factor 1α; sVEGFR-2=soluble VEGF receptor 2; sVEGFR-3=soluble VEGF receptor 3; VEGF=vascular endothelial growth factor.
P-values <0.05 are underlined and shown in bold.
a
Wilcoxon rank-sum test comparing carcinoid with pNET.